Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | PLK1 | P53350 | 3/20 | 0.54 |
| ▸ | BRD4 | O60885 | 4/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 7/20 | 0.46 |
| ▸ | CCND1 | P24385 | 6/20 | 0.46 |
| ▸ | CCND2 | P30279 | 4/20 | 0.46 |
| ▸ | CCND3 | P30281 | 4/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917086 | 1.00 | EGFR (0.54) | EGFRPLK1BRD4ERBB3SYK | |
| SCHEMBL1916873 | 0.84 | GSK3B (0.46) | PLK1SYKCDK4CCND1AURKA | |
| SCHEMBL1916584 | 0.82 | AXL (0.48) | EGFRPLK1BRD4CDK4CCND1 | |
| SCHEMBL1916948 | 0.79 | JAK3 (0.44) | EGFRPLK1BRD4SYKCDK4 | |
| SCHEMBL1916950 | 0.79 | JAK3 (0.44) | EGFRPLK1BRD4SYKCDK4 | |
| SCHEMBL1917742 | 0.77 | SYK (0.45) | EGFRPLK1SYKCDK2PAK4 | |
| SCHEMBL1917745 | 0.77 | SYK (0.45) | EGFRPLK1SYKCDK2PAK4 | |
| SCHEMBL14847406 | 0.77 | EGFR (0.62) | EGFRPLK1BRD4SYKCDK4 | |
| SCHEMBL1917075 | 0.77 | KDR (0.42) | PLK1SYKINSRKDR | |
| SCHEMBL1917073 | 0.77 | KDR (0.42) | PLK1SYKINSRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | EGFR 824/4885PLK1 391/4885BRD4 2169/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | EGFR 478/4885PLK1 930/4885BRD4 2420/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | EGFR 824/4885PLK1 391/4885BRD4 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.